Proteasome inhibitors in cancer therapy: Lessons from the first decade

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1649-1657

  Orlowski, Robert Z ^a   Kuhn, Deborah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CARFILZOMIB; CYTARABINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GABAPENTIN; IRINOTECAN; MELPHALAN; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CHEMOSENSITIZATION; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; FATIGUE; FEVER; FLUID RETENTION; HEADACHE; HODGKIN DISEASE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LEG PAIN; LUNG NON SMALL CELL CANCER; MALAISE; MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STANDING; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 41549133200     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-2218     Document Type: Review

References (123)

1. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitinproteasome system and onto human diseases and drug targeting. Cell Death Differ 2005;12:1178-90.
2. Demartino GN, Gillette TG. Proteasomes: machines for all reasons. Cell 2007;129:659-62.
3. Orlowski M, Wilk S. Catalytic activities of the 20 S proteasome, amulticatalytic proteinase complex. Arch Biochem Biophys 2000;383:1-16.
4. Touitou R, Richardson J, Bose S, et al. A degradation signal located in the C-terminus of p21WAF1/CIP1is a binding site for the C8 α-subunit of the 20S proteasome. EMBO J 2001;20:2367-75.
5. Li X, Amazit L, Long W, et al. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGγ-proteasome pathway. Mol Cell 2007;26:831-42.
6. Tambyrajah WS, Bowler LD, Medina-Palazon C, Sinclair AJ. Cell cycle-dependent caspase-like activity that cleaves p27(KIP1) is the β(1) subunit of the 20S proteasome. Arch Biochem Biophys 2007;466:186-93.
7. Vinitsky A, Michaud C, Powers JC, Orlowski M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 1992;31:9421-8.
8. Vinitsky A, Cardozo C, Sepp-Lorenzino L, Michaud C, Orlowski M. Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes. J Biol Chem 1994;269:29860-6.
9. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-8.
10. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
11. Sin N, Kim KB, Elofsson M, et al. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 1999;9:2283- 8.
12. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-90.
13. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-91.
14. Stapnes C, Doskeland AP, Hatfield K, et al. The proteasome inhibitors bortezomib and PR-171have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 2007;136:814-28.
15. Fenteany G, Schreiber SL. Lactacystin, proteasome function, and cell fate. J Biol Chem 1998;273:8545-8.
16. Feling RH, Buchanan GO, Mincer TJ, et al. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 2003;42:355-7.
17. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005;8:407-19.
18. Imajoh-Ohmi KT, Sugiyama S, Tanaka K, Omura S, Kikuchi H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 1995;217:1070-7.
19. Shinohara K, Tomioka M, Nakano H, et al. Apoptosis induction resulting from proteasome inhibition. Biochem J 1996;317:385-8.
20. Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis. Br J Cancer 1998;77:1103-7.
21. Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998;58:4342-8.
22. Orlowski RZ, Baldwin AS. NF-κB as a therapeutic target in cancer. Trends Mol Med 2002;8:385-9.
23. Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science1996;274:784-7.
24. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced antitumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;5:412-7.
25. Cusack JC, Jr., Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 2001;61:3535-40.
26. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood1996;87:1104-12.
27. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
28. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-44.
29. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
30. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 2002;99:4079-86.
31. Bennouna J, Delord JP, Campone M, Pinel M-C. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 2008;14:1610-17.
32. Choy H, Park C, Yao M. Current status and future prospect for satraplatin: an oral platinum analogue. Clin Cancer Res 2008;14:1618-23.
33. Gautschi O, Heighway J, Mack PC, et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1624-33.
34. Lee JL, Swain SM. The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 2008;14:1643-9.
35. Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 2008;14:1650-7.
36. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003;9:6316-25.
37. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9.
38. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005;102:8567-72.
39. Nawrocki ST, Carew JS, Pino MS, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005;65:11658-66.
40. Nawrocki ST, Carew JS, Dunner K, Jr., et al. Bortezomib inhibits PKR-like endoplasmic reticulum(ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005;65:11510-9.
41. Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16.
42. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006;57:33-47.
43. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007;21:30-6.
44. Hideshima T, Podar K, Chauhan D, et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiplemyeloma cells. Oncogene 2004;23:8766-76.
45. Robertson JD, Datta K, Biswal SS, Kehrer JP. Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor-induced apoptosis. Biochem J 1999;344:477-85.
46. Voorhees PM, Chen Q, Kuhn DJ, et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in pre-clinical models of multiple myeloma. Clin Cancer Res 2007;13:6469-78.
47. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092-100.
48. Orlowski RZ, Small GW, Shi YY. Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 2002;277:27864-71.
49. Small GW, Shi YY, Edmund NA, et al. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 2004;66:1478-90.
50. Shi YY, Small GW, Orlowski RZ. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 2006;100:33-47.
51. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107:4053-62.
52. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
53. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
54. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-21.
55. Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004;10:3371-6.
56. Blaney SM, Bernstein M, Neville K, et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 2004;22:4804-9.
57. Dy GK, Thomas JP, Wilding G, et al. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 2005;11:3410-6.
58. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
59. Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory-multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006;106:1316-9.
60. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
61. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed-multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60.
62. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84.
63. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-75.
64. Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib inmantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007;18:116-21.
65. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-74.
66. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:3320-5.
67. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570-5.
68. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor a response with clinical activity. J Clin Oncol 2006;24:2105-12.
69. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005;90:1655- 8.
70. Wechalekar A, Gillmore J, Lachmann H, Offer M, Hawkins P. Efficacy and safety of bortezomib in systemic AL amyloidosis-a preliminary report [abstract 129]. Blood 2006;108:42a.
71. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiplemyeloma. Blood 2005;106:3777-84.
72. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20.
73. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
74. Ling YH, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 2002;1:841- 9.
75. Loo TW, Clarke DM. Superfolding of the partially unfolded core-glycosylated intermediate of human Pglycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J Biol Chem 1998;273:14671-4.
76. Loo TW, Clarke DM. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J1999;7:1724-32.
77. Aghajanian C, Dizon DS, Sabbatini P, et al. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 2005;23:5943-9.
78. Messersmith WA, Baker SD, Lassiter L, et al. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 2006;12:1270-5.
79. Ryan DP, O'Neil BH, Supko JG, et al. A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 2006;107:2688-97.
80. Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006;24:937-44.
81. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005;105:3058-65.
82. Barlogie B, Shaughnessy JD, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
83. Ma C, Mandrekar SJ, Alberts SR, et al. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 2007;59:207-15.
84. Voortman J, Smit EF, Honeywell R, et al. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res 2007;13:3642-51.
85. Biehn SE, Moore DT, Voorhees PM, et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2007;86:211-6.
86. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901.
87. Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007;5:118-47.
88. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-83.
89. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498-505.
90. Harousseau JL, Marit G, Caillot D, et al. VELCADE/dexamethasone versus VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: an interim analysis of the IFM 2005-01 randomized multicenter phase III trial [abstract 56]. Blood 2006;108:21a.
91. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 2006;108:2165-72.
92. San Miguel JF, Schlag R, Khuageva N, et al. MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma [abstract 76]. Blood 2007;110:31a.
93. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007;12:235-9.
94. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176-85.
95. Weigert O, Pastore A, Rieken M, et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007;21:524-8.
96. Canfield SE, Zhu K, Williams SA, McConkey DJ. Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther 2006;5:2043-50.
97. Ruan J, Leonard JP. Mantle cell lymphoma: current concept in biology and treatment. Cancer Treat Res 2006;131:141-59.
98. Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296-303.
99. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast 2006;15:718-27.
100. Yang CH, Gonzalez-Angulo AM, Reuben JM, et al. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 2006;17:813-7.
101. Ishii Y, Pirkmaier A, Alvarez JV, et al. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst 2006;98:1238-47.
102. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-30.
103. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 2007;12:131-44.
104. Dolcet X, Llobet D, Encinas M, et al. Proteasome inhibitors induce death but activate NF-κB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 2006;281:22118-30.
105. Masdehors P, Merle-Beral H, Maloum K, et al. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 2000;96:269-74.
106. Faderl S, Rai K, Gribben J, et al. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 2006;107:916 -24.
107. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem 2008;103:270-83.
108. Bhandari M, Jagannath S. Repeated complete responses with bortezomib in a heavily pretreated primary refractory patient with light chain multiple myeloma. Clin Lymphoma Myeloma 2007;7:373-5.
109. Conner TM, Doan QCD, LeBlanc AL, Walters IB, Beveridge RA. An observational, retrospective analysis of retreatment with bortezomib of mulitple myeloma (MM)patients [abstract 3531]. Blood 2006;108:1007a.
110. Wolf JL, Richardson P, Schuster M, et al. Utility of bortezomib retreatment for patients with relapsed multiple myeloma [abstract 3532]. Blood 2006;108:1008a.
111. Sharma RC, Inoue S, Roitelman J, Schimke RT, Simoni RD. Peptide transport by the multidrug resistance pump. J Biol Chem 1992;267:5731-4.
112. Inoue S, Sharma RC, Schimke RT, Simoni RD. Cellular detoxification of tripeptidyl aldehydes by an aldoketo reductase. J Biol Chem 1993;268:5894-8.
113. Rumpold H, Salvador C, Wolf AM, et al. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun 2007;361:549-54.
114. Nakamura T, Tanaka K, Matsunobu T, et al. The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. Int J Oncol 2007;31:803-11.
115. Schmidmaier R, Baumann P, Bumeder I, et al. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol 2007;79:240-3.
116. Ruiz S, Krupnik Y, Keating M, et al. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 2006;5:1836-43.
117. Orlowski RZ, Stewart K, Vallone M, et al. Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: phase I results [abstract 409]. Blood 2007;110:127a.
118. Alsina M, Trudel S, Vallone M, et al. Phase I single agent antitumor activity of twice weekly-consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies [abstract 411]. Blood 2007;110:128a.
119. Rivett AJ, Hearn AR. Proteasome function in antigen presentation: immunoproteasome complexes, Peptide production, and interactions with viral proteins. Curr Protein Pept Sci 2004;5:153-61.
120. Orlowski RZ, Kuhn DJ, Small GW, Michaud C, Orlowski M. Identification of novel inhibitors that specifically target the immunoproteasome, and selectively induce apoptosis in multiple myeloma and other immunoproteasome-expressing model systems [abstract 248]. Blood 2005;106:76a.
121. Ho YK, Bargagna-Mohan P, Wehenkel M, Mohan R, Kim KB. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol 2007;14:419-30.
122. Altun M, Galardy PJ, Shringarpure R, et al. Effects of PS-341on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 2005;65:7896-901.
123. Smiley ST, Reers M, Mottola-Hartshorn C, et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A 1991;88:3671-5